{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Jeiziner C"],"pubmed_abstract":["<h4>Purpose</h4>Pharmacogenetic (PGx) panel testing could help to determine the heritable component of a rheumatoid arthritis (RA) patient's susceptibility for therapy failure and/or adverse drug reactions (ADRs) from methotrexate (MTX). Considering the literature mentioning the potential applicability of PGx panel testing within MTX regimens, we discuss the case of a patient who was treated with MTX, suffered from ADRs, and obtained a reactive PGx panel testing.<h4>Genotyping</h4>We used a commercial PGx panel test involving the ABC-transporters P-glycoprotein (P-gp; gene: <i>ABCB1</i>), and breast cancer resistance protein (BCRP; gene: <i>ABCG2</i>), the solute carriers reduced folate carrier 1 (RFC1; gene: <i>SLC19A1</i>), and organic anion transporting polypeptide 1B1 (OATP1B1; gene: <"],"journal":["Pharmacogenomics and personalized medicine"],"pagination":["465-475"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9109898"],"repository":["biostudies-literature"],"pubmed_title":["Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? - A Case Report."],"pmcid":["PMC9109898"],"pubmed_authors":["Meyer Zu Schwabedissen HE","Allemann SS","Jeiziner C","Hersberger KE"],"additional_accession":[]},"is_claimable":false,"name":"Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? - A Case Report.","description":"<h4>Purpose</h4>Pharmacogenetic (PGx) panel testing could help to determine the heritable component of a rheumatoid arthritis (RA) patient's susceptibility for therapy failure and/or adverse drug reactions (ADRs) from methotrexate (MTX). Considering the literature mentioning the potential applicability of PGx panel testing within MTX regimens, we discuss the case of a patient who was treated with MTX, suffered from ADRs, and obtained a reactive PGx panel testing.<h4>Genotyping</h4>We used a commercial PGx panel test involving the ABC-transporters P-glycoprotein (P-gp; gene: <i>ABCB1</i>), and breast cancer resistance protein (BCRP; gene: <i>ABCG2</i>), the solute carriers reduced folate carrier 1 (RFC1; gene: <i>SLC19A1</i>), and organic anion transporting polypeptide 1B1 (OATP1B1; gene: <","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-05T11:03:17.441Z","creation":"2025-04-05T11:03:17.441Z"},"accession":"S-EPMC9109898","cross_references":{"pubmed":["35586477"],"doi":["10.2147/PGPM.S354011"]}}